RVMD News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

RV

Mkt Cap

$38.17B

Volume

2.69M

Next Earnings

November 4th

Loading chart

RV

RVMDRevolution Medicines, Inc. Common Stock

RVMD

Pay with—

Available Balance0.00

RV

Mkt Cap

$40.57B

Volume

2.69M

Next Earnings

November 4th

Chart Financials Earnings News About Insider Filings

These 2 Stocks Have Run Circles Around the Magnificent Seven This Year, and Wall Street Says There Is More Upside AheadRevolution Medicines and Oruka Therapeutics have significantly outperformed the Magnificent Seven tech stocks this year, both more than doubling. Revolution Medicines gained FDA approval for Rasonque, a pancreatic cancer treatment with blockbuster potential ($20.8B peak revenue projected). Oruka Therapeutics is developing ORKA-001 for psoriasis with promising Phase 2 results and convenient once-yearly dosing. While Wall Street sees substantial upside (36% for RVMD, 95% for ORKA), both stocks carry significant risk due to clinical uncertainty and limited approval history.The Motley Fool · Oct 15, 2026

Amgen vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026?The article compares Amgen, an established biotech giant with $36.7B in revenue and strong profitability, against Revolution Medicines, a clinical-stage oncology company with no approved products but a breakthrough cancer therapy (Daraxonrasib) that showed 50%+ reduction in death risk for metastatic pancreatic cancer. The author recommends Revolution Medicines for long-term investors willing to accept biotech risk, citing the paradigm-shifting potential of its RAS-targeted cancer pipeline, despite current losses and competitive pressures.The Motley Fool · Sep 11, 2026

New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung CancerRevolution Medicines announced publication of Phase 1/2 clinical trial data for RASONQUE (daraxonrasib) in previously treated RAS mutant non-small cell lung cancer in the New England Journal of Medicine. The trial showed a 42% objective response rate and 16.0 months median overall survival in a docetaxel-naïve subgroup, with a manageable safety profile. Results support the ongoing Phase 3 RASolve 301 trial.GlobeNewswire Inc. · Sep 2, 2026

Revolution Medicines Won FDA Approval One Month After Filing. Analysts See $11.5 Billion in Peak Sales. Is the Stock Still a Buy After Skyrocketing More Than 5X?Revolution Medicines received rapid FDA approval for Rasonque, a novel pancreatic cancer treatment using a RAS inhibitor mechanism. The drug demonstrated strong Phase 3 trial results and analysts project peak annual sales of $11.5 billion. The stock has surged 178% year-to-date, with potential for further expansion into other cancer indications affecting 30% of solid tumors.The Motley Fool · Aug 28, 2026

Onco360® Has Been Selected as a National Pharmacy Partner for RASONQUE™ (daraxonrasib)Onco360, the nation's leading independent specialty pharmacy, has been selected as a pharmacy partner by Revolution Medicines for the launch of RASONQUE (daraxonrasib), a RAS GTPase inhibitor for metastatic pancreatic adenocarcinoma. The drug showed significant clinical benefits in the phase 3 RASolute-302 trial, with median PFS of 7.3 months and OS of 13.2 months in RAS G12 mutation patients compared to 3.5 months and 6.6 months respectively for chemotherapy.GlobeNewswire Inc. · Aug 26, 2026

U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic CancerThe FDA has approved RASONQUE (daraxonrasib), developed by Revolution Medicines, as the first targeted RAS inhibitor for treating metastatic pancreatic adenocarcinoma in patients who have received prior systemic therapy or are not candidates for multiagent chemotherapy. In the Phase 3 RASolute 302 trial, RASONQUE reduced the risk of death by 60% compared to chemotherapy, with median overall survival of 13.2 months versus 6.7 months, and demonstrated manageable safety with improved quality of life measures.GlobeNewswire Inc. · Aug 26, 2026

ERASCA DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Erasca, Inc. Investors to Secure Counsel Before Important August 10 Deadline in Securities Class Action – ERASA securities class action lawsuit has been filed against Erasca, Inc. and its executives for allegedly making false and misleading statements about its lead oncology drug candidate ERAS-0015. The company is accused of improperly comparing its drug to a competitor's candidate and failing to disclose patent and trade secret disputes. Investors who purchased Erasca stock between January 14, 2025 and April 26, 2026 must act by August 10, 2026 to serve as lead plaintiff.GlobeNewswire Inc. · Aug 8, 2026

ERASCA LEAD PLAINTIFF DEADLINE AUGUST 10th: Bragar Eagel & Squire, P.C. Reminds Erasca, Inc. (ERAS) Investors with Large Losses to Contact the Firm Regarding their RightsA class action lawsuit has been filed against Erasca, Inc. alleging that the company made false and misleading statements regarding its ERAS-0015 drug candidate. The lawsuit claims the preclinical data was based on improper comparisons and lacked reasonable basis. Following a patent infringement allegation from Revolution Medicines disclosed on April 28, 2026, Erasca's stock price declined approximately 48% from $19.15 to $9.90 per share. Investors have until August 10, 2026 to apply as lead plaintiff.GlobeNewswire Inc. · Aug 7, 2026

ERAS 3-DAY DEADLINE ALERT: Erasca, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit– Hagens BermanHagens Berman is investigating securities fraud claims against Erasca, Inc. for allegedly misleading investors about its lead oncology drug ERAS-0015's competitive advantages, safety profile, and intellectual property protections. The company faces patent infringement allegations from Revolution Medicines and reported a patient death in clinical trials, triggering a $2.8 billion market capitalization loss. Investors with substantial losses can serve as lead plaintiffs with an August 10, 2026 deadline.GlobeNewswire Inc. · Aug 7, 2026

Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Reed Kathrein at Hagens Berman Sobol Shapiro LLP Before Application DeadlineHagens Berman is investigating securities fraud claims against Erasca, Inc. for allegedly misleading investors about its lead oncology drug ERAS-0015's competitive advantages, safety profile, and intellectual property protections. The company faces patent infringement allegations from Revolution Medicines and reported a patient death in clinical trials. These disclosures in late April 2026 triggered a sharp stock decline, erasing over $2.8 billion in market capitalization. The lead plaintiff deadline is August 10, 2026.GlobeNewswire Inc. · Aug 6, 2026

to start trading

RV

RVMDRevolution Medicines, Inc. Common Stock

RVMD

Pay with—

Available Balance0.00

Your PositionYou don't own any RVMD yet.

Related Tickers

Earnings